irl-1620 and Prostatic-Neoplasms

IRL-1620, a potent endothelin B receptor agonist, enhanced the efficacy of paclitaxel in a breast tumor model, but its effect in prostate cancer is not known. The present study was conducted to evaluate the effect of IRL-1620 on tumor perfusion, uptake of [(14)C]-doxorubicin in the tumor and efficacy of doxorubicin (DOX), and 5-flurouracil (5-FU) in a rat prostate tumor model.. JHU-4 (Mat-Lu) cells inoculated prostate tumor model in Copenhagen rats was used for the study.. Administration of IRL-1620 (3 nmol/kg, i.v) significantly increased (102.8%) prostate tumor perfusion and tumor uptake of [(14)C]-doxorubicin (115%) compared to vehicle treated rats. Results of the efficacy study demonstrate that IRL-1620 administration 15 min prior to DOX (5 mg/kg) or 5-FU (50 mg/kg) on every third day for a total of four doses significantly reduced tumor volume compared to vehicle treated rats.. IRL-1620 significantly enhanced the uptake and efficacy of anticancer agents in prostate cancer.

Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Body Weight; Doxorubicin; Endothelins; Fluorouracil; Male; Peptide Fragments; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Receptor, Endothelin B; Vasodilation; Vasodilator Agents